-

Shareholder Alert: Robbins LLP Informs Shareholders of Class Action Filed Against NAPCO Security Technologies, Inc. (NSSC)

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs investors that a shareholder filed a class action on behalf of persons or entities who: (1) purchased or otherwise acquired publicly traded NAPCO Security Technologies, Inc. (NASDAQ: NSSC) securities between November 7, 2022 and August 18, 2023. NAPCO engages in the development, manufacture, and distribution of security products. Its products include access control systems, door security products, intrusion and fire alarm systems, video surveillance products, and cellular communication services.

For more information, submit a form, email Aaron Dumas, Jr., or give us a call at (800) 350-6003.

What is this Case About: NAPCO Security Technologies, Inc. (NSSC) Failed to Disclose Material Weaknesses with Internal Controls Regarding Costs of Goods Sold

According to the complaint, during the class period, defendants failed to disclose that: (1) NAPCO failed to address any material weaknesses with internal controls regarding COGS and inventory; (2) NAPCO downplayed the severity of material weaknesses regarding their internal controls; (3) NAPCO’s unaudited financial statements from September 30, 2022 to the present included “certain errors” such as overstating inventory and understanding net COGS, resulting in overstated gross profit, operating income and net income for each period; and (4) as a result, NAPCO would need to restate its previously filed unaudited financial statements for certain periods.

On August 18, 2023, NAPCO announced it would restate its unaudited financial statements from September 30, 2022 to the present. On this news, NAPCO's share price fell $17.30, or over 45%, to close at $21.11 on August 21, 2023.

What Now: Similarly situated shareholders may be eligible to participate in the class action against NAPCO Security Technologies, Inc. Shareholders who want to act as lead plaintiff for the class must file their motion for lead plaintiff by October 30, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: Some law firms issuing releases about this matter do not actually litigate securities class actions; Robbins LLP does. A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders.

To be notified if a class action against NAPCO Securities Technologies, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:NSSC

Release Summary
NAPCO Security Technologies, Inc. (NSSC) Failed to Disclose Material Weaknesses with Internal Controls Regarding Costs of Goods Sold
Release Versions
$Cashtags

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Stockholder Notice: Robbins LLP Informs Investors of the Atara Biotherapeutics, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Atara Biotherapeutics, Inc. (NASDAQ: ATRA) securities between May 20, 2024 and January 9, 2026. Atara develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the U.S. and the United Kingdom (“U.K.”). The Company’s lead product candidate is tabelecleucel (also referred to as tab-cel or EBVALLO), a T-ce...

Stockholder Notice: Robbins LLP Informs Investors of the Coty Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Coty Inc. (NYSE: COTY) common stock between November 5, 2025 and February 4, 2026. Coty together with its subsidiaries, manufactures, markets, distributes, and sells branded beauty products worldwide. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Inves...

Investor Notice: Robbins LLP Informs Investors of the Lufax Holding Ltd. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Lufax Holding Ltd. (NYSE: LU) securities between April 7, 2023 and January 26, 2025. Lufax Holding Ltd engages in the retail credit and enablement business to borrowers and institutions in China. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigat...
Back to Newsroom